Athira Pharma, Inc. (NASDAQ:LONA – Get Free Report) was the target of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 23,651 shares, a decrease of 41.3% from the August 31st total of 40,293 shares. Approximately 0.3% of the shares of the company are sold short. Based on an average trading volume of 64,689 shares, the days-to-cover ratio is presently 0.4 days.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on LONA shares. Mizuho cut their target price on shares of Athira Pharma from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Wednesday, August 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a research report on Friday, August 7th. Finally, Citizens Jmp lowered their price objective on shares of Athira Pharma from $18.00 to $17.00 and set a “market outperform” rating on the stock in a research report on Monday, August 17th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $17.33.
Read Our Latest Research Report on LONA
Hedge Funds Weigh In On Athira Pharma
Athira Pharma Trading Up 1.1%
Shares of NASDAQ:LONA traded up $0.04 during midday trading on Wednesday, hitting $3.55. The stock had a trading volume of 19,529 shares, compared to its average volume of 60,861. The company has a market capitalization of $33.35 million, a PE ratio of -0.84 and a beta of 2.05. The stock has a 50 day moving average price of $7.13 and a two-hundred day moving average price of $8.49. Athira Pharma has a 1 year low of $2.21 and a 1 year high of $14.21.
Athira Pharma (NASDAQ:LONA – Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.20). As a group, equities analysts expect that Athira Pharma will post -2.67 EPS for the current year.
About Athira Pharma
Athira Pharma, Inc is a biotechnology company focused on developing regenerative medicines for diseases involving neurodegeneration and neurological decline. The company’s research is based on the hepatocyte growth factor (HGF) pathway, which it believes may support neuronal health, repair, and regeneration.
Athira’s lead investigational product is fosgonimeton (also known as ATH-1017), a small-molecule therapy designed to activate the HGF/MET system. The treatment has been studied for Alzheimer’s disease and other neurological conditions, although it remains investigational and has not been approved for commercial use.
Athira was founded in 2011 and is based in the United States.
Read More
- Five stocks we like better than Athira Pharma
- 3 Healthcare Dividend Stocks Offering More Than Just Income
- AI Uncertainty Is Rising, But These 3 Chip ETFs Still Have Momentum
- Arhaus Has New Momentum—Could Other Furniture Stocks Be Next?
- Can Boxabl Turn Modular Homes Into AI Data Center Infrastructure?
Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
